Request Deal Involvement

Merck completed the acquisition of VelosBio from Arix and Pappas Capital for $2.75bn.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Optimum Strategic Communications

pr advisors

Optimum Strategic Communications

Gibson Dunn & Crutcher

legal advisors

Gibson Dunn & Crutcher

JP Morgan

financial advisors

JP Morgan

Cravath Swaine & Moore

legal advisors to financial advisors

Cravath Swaine & Moore

Gasthalter & Co

pr advisors

Gasthalter & Co

KKH Advisors

pr advisors

KKH Advisors

Cooley

legal advisors

Cooley

Centerview Partners

financial advisors

Centerview Partners

or

Principals

ARIX BIOSCIENCE

vendor

ARIX BIOSCIENCE

MERCK & CO

bidder

MERCK & CO

PAPPAS CAPITAL

vendor

PAPPAS CAPITAL

VELOSBIO INC

target

VELOSBIO INC

VENROCK

vendor

VENROCK

CHIESI VENTURES

vendor

CHIESI VENTURES

ORBIMED ADVISORS LLC

vendor

ORBIMED ADVISORS LLC

TAKEDA VENTURES

vendor

TAKEDA VENTURES

SOFINNOVA PARTNERS

vendor

SOFINNOVA PARTNERS

DECHENG CAPITAL LLC

vendor

DECHENG CAPITAL LLC

FORESITE CAPITAL MANAGEMENT LLC

vendor

FORESITE CAPITAL MANAGEMENT LLC

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite